178 related articles for article (PubMed ID: 12476597)
1. Head and neck cancer: managing xerostomia and other treatment induced side effects.
Gosselin TK; Pavilonis H
ORL Head Neck Nurs; 2002; 20(4):15-22. PubMed ID: 12476597
[TBL] [Abstract][Full Text] [Related]
2. Evaluation, prevention and management of radiotherapy-induced xerostomia in head and neck cancer patients.
de Castro G; Federico MH
Curr Opin Oncol; 2006 May; 18(3):266-70. PubMed ID: 16552239
[TBL] [Abstract][Full Text] [Related]
3. Radiation-induced xerostomia in patients with head and neck cancer: pathogenesis, impact on quality of life, and management.
Chambers MS; Garden AS; Kies MS; Martin JW
Head Neck; 2004 Sep; 26(9):796-807. PubMed ID: 15350026
[TBL] [Abstract][Full Text] [Related]
4. Pathophysiology and management of radiation-induced xerostomia.
Berk LB; Shivnani AT; Small W
J Support Oncol; 2005; 3(3):191-200. PubMed ID: 15915820
[TBL] [Abstract][Full Text] [Related]
5. Radiotherapy alone, versus radiotherapy with amifostine 3 times weekly, versus radiotherapy with amifostine 5 times weekly: A prospective randomized study in squamous cell head and neck cancer.
Jellema AP; Slotman BJ; Muller MJ; Leemans CR; Smeele LE; Hoekman K; Aaronson NK; Langendijk JA
Cancer; 2006 Aug; 107(3):544-53. PubMed ID: 16804929
[TBL] [Abstract][Full Text] [Related]
6. Phase II trial of subcutaneous amifostine in patients undergoing radiation therapy for head and neck cancer.
Anné PR
Semin Oncol; 2002 Dec; 29(6 Suppl 19):80-3. PubMed ID: 12577250
[TBL] [Abstract][Full Text] [Related]
7. A phase II study to assess the efficacy of amifostine for submandibular/sublingual salivary sparing during the treatment of head and neck cancer with intensity modulated radiation therapy for parotid salivary sparing.
Rosenthal DI; Chambers MS; Weber RS; Eisbruch A
Semin Oncol; 2004 Dec; 31(6 Suppl 18):25-8. PubMed ID: 15726519
[TBL] [Abstract][Full Text] [Related]
8. Managing complications of radiation therapy in head and neck cancer patients: Part I. Management of xerostomia.
Ngeow WC; Chai WL; Rahman RA; Ramli R
Singapore Dent J; 2006 Dec; 28(1):1-3. PubMed ID: 17378333
[TBL] [Abstract][Full Text] [Related]
9. Amifostine reduces radiation therapy-induced dry mouth in head and neck cancer patients.
Oncology (Williston Park); 2004 Sep; 18(10):1314, 1316. PubMed ID: 15526835
[No Abstract] [Full Text] [Related]
10. Randomized phase III trial of postoperative radiochemotherapy +/- amifostine in head and neck cancer. Is there evidence for radioprotection?
Vacha P; Fehlauer F; Mahlmann B; Marx M; Hinke A; Sommer K; Richter E; Feyerabend T
Strahlenther Onkol; 2003 Jun; 179(6):385-9. PubMed ID: 12789464
[TBL] [Abstract][Full Text] [Related]
11. Using technology to decrease xerostomia for head and neck cancer patients treated with radiation therapy.
Amosson CM; Teh BS; Mai WY; Woo SY; Chiu JK; Donovan DT; Parke R; Carpenter LS; Lu HH; Grant WH; Butler EB
Semin Oncol; 2002 Dec; 29(6 Suppl 19):71-9. PubMed ID: 12577249
[TBL] [Abstract][Full Text] [Related]
12. Toxicity and compliance of subcutaneous amifostine in patients undergoing postoperative intensity-modulated radiation therapy for head and neck cancer.
Thorstad WL; Chao KS; Haughey B
Semin Oncol; 2004 Dec; 31(6 Suppl 18):8-12. PubMed ID: 15726516
[TBL] [Abstract][Full Text] [Related]
13. The role of saliva in oral health: strategies for prevention and management of xerostomia.
Brosky ME
J Support Oncol; 2007 May; 5(5):215-25. PubMed ID: 17564151
[TBL] [Abstract][Full Text] [Related]
14. Influence of intravenous amifostine on xerostomia, tumor control, and survival after radiotherapy for head-and- neck cancer: 2-year follow-up of a prospective, randomized, phase III trial.
Wasserman TH; Brizel DM; Henke M; Monnier A; Eschwege F; Sauer R; Strnad V
Int J Radiat Oncol Biol Phys; 2005 Nov; 63(4):985-90. PubMed ID: 16253773
[TBL] [Abstract][Full Text] [Related]
15. Intravenous amifostine during chemoradiotherapy for head-and-neck cancer: a randomized placebo-controlled phase III study.
Buentzel J; Micke O; Adamietz IA; Monnier A; Glatzel M; de Vries A
Int J Radiat Oncol Biol Phys; 2006 Mar; 64(3):684-91. PubMed ID: 16243440
[TBL] [Abstract][Full Text] [Related]
16. Radiation-induced xerostomia.
Chambers MS; Rosenthal DI; Weber RS
Head Neck; 2007 Jan; 29(1):58-63. PubMed ID: 16906511
[TBL] [Abstract][Full Text] [Related]
17. Symptom management in radiation oncology: acute and long-term side effects.
Robbins MA; Gosselin TK
Am J Nurs; 2002 Apr; 102 Suppl 4():32-6; quiz 49-52. PubMed ID: 11953536
[No Abstract] [Full Text] [Related]
18. Treatment for radiation-induced xerostomia. An innovative remedy.
Kusler DL; Rambur BA
Cancer Nurs; 1992 Jun; 15(3):191-5. PubMed ID: 1611604
[TBL] [Abstract][Full Text] [Related]
19. Feasibility and efficacy of subcutaneous amifostine therapy in patients with head and neck cancer treated with curative accelerated concomitant-boost radiation therapy.
Ozsahin M; Betz M; Matzinger O; Bron L; Luthi F; Pasche P; Azria D; Mirimanoff RO; Zouhair A
Arch Otolaryngol Head Neck Surg; 2006 Feb; 132(2):141-5. PubMed ID: 16490870
[TBL] [Abstract][Full Text] [Related]
20. Effect of pilocarpine during radiation therapy: results of RTOG 97-09, a phase III randomized study in head and neck cancer patients.
Scarantino C; LeVeque F; Swann RS; White R; Schulsinger A; Hodson DI; Meredith R; Foote R; Brachman D; Lee N
J Support Oncol; 2006 May; 4(5):252-8. PubMed ID: 16724649
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
